Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26984268 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL17788033 | 0.90 | SIGMAR1 (0.44) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL27128343 | 0.87 | KDM1A (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL26984154 | 0.87 | KDM1A (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL22473262 | 0.85 | ADAM10 (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL26984155 | 0.85 | ADAM10 (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL3736894 | 0.85 | TMEM97 (0.44) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL28680130 | 0.84 | KDM1A (0.48) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL26984159 | 0.84 | KDM1A (0.48) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 | |
| SCHEMBL20012064 | 0.83 | SIGMAR1 (0.47) | SIGMAR1TMEM97PARP1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | SIGMAR1 4459/4885TMEM97 3777/4885PARP1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.